Predictive Clinical and Biological Parameters in Acute Leukemia Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

  • End date
    May 22, 2024
  • participants needed
  • sponsor
    Institut Paoli-Calmettes
Updated on 22 January 2021
myelodysplastic syndromes
acute leukemia
myeloproliferative disorder
bone marrow procedure
biological factors


HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies.

HEMATO-BIO primary outcome measure is to identify molecular, genomic and epigenetic, pharmacologic and immunophenotypic alteration in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by collecting, at diagnosis and/or complete remission and/or

  • tumor samples: marrow aspiration, blood sampling.
  • non-tumor samples: skin biopsy, buccal swab . from 650 patients treated at our cancer center.

Condition Bone marrow disorder, Preleukemia, MYELOPROLIFERATIVE DISORDER, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), Acute Leukemia, Myeloproliferative Neoplasms, myelodysplastic syndromes, myeloproliferative neoplasm, myeloproliferative disorders, myelodysplastic syndrome (mds), acute leukemias
Treatment blood sampling, Skin Biopsy, Buccal swab, Bone marrow aspirate
Clinical Study IdentifierNCT02320656
SponsorInstitut Paoli-Calmettes
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: MYELODYSPLASTIC SYNDROME or Acute Leukemia or Preleukemia or MYELOPROLIFERATIVE DISORDER?
Do you have any of these conditions: Acute Leukemia or Bone marrow disorder or Myelodysplastic Syndromes (MDS) or myeloproliferative disorders or myelodysplastic syndrome (mds) or myelopr...?
acute leukemia, myelodysplastic syndrome or myeloproliferative disease
age > 18
affiliated to the French Social Security Systm
signed informed consent

Exclusion Criteria

patients deprived of liberty or placed under the authority of a tutor
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note